GSA Capital Partners LLP Sells 27,220 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

GSA Capital Partners LLP reduced its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 42.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,662 shares of the company’s stock after selling 27,220 shares during the period. GSA Capital Partners LLP owned 0.07% of 4D Molecular Therapeutics worth $407,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of FDMT. nVerses Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $40,000. Values First Advisors Inc. acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $57,000. Quest Partners LLC increased its position in 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after acquiring an additional 3,922 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $108,000. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $7.99 on Friday. The firm has a market capitalization of $369.38 million, a PE ratio of -2.80 and a beta of 2.82. The stock has a fifty day simple moving average of $9.72 and a two-hundred day simple moving average of $16.66. 4D Molecular Therapeutics, Inc. has a 52-week low of $7.32 and a 52-week high of $36.25.

Wall Street Analysts Forecast Growth

FDMT has been the topic of several recent research reports. Leerink Partners reaffirmed an “outperform” rating and issued a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Finally, Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.